Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
cache
Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of
nab
-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.